| General Information of Drug Metabolite (DM) (ID: DM018658) |
| DM Name |
Ala-TFV
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Metabolizing This DM |
| DME Name |
DME ID |
Product |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Unclear - Unclear |
GS-7340
|
[1] , [2] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| GS-7340 |
DR5334
|
Approved |
Hepatitis B virus infection |
|
|
| References |
| 1 |
Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy
|
| 2 |
Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
